Lawrence Steinman

Publication Details

  • Antigen specific immunotherapy of multiple sclerosis JOURNAL OF CLINICAL IMMUNOLOGY Steinman, L., Conlon, P. 2001; 21 (2): 93-98


    The development of antigen specific therapy for multiple sclerosis (MS) involves specifically suppressing undesired immune responses targeting the myelin sheath and underlying axon. We have recently reported some success with altered peptide ligands for a major target of the autoimmune response in MS. Antigen specific therapy has the potential to suppress undesirable autoimmunity, while leaving the rest of the immune system intact. Induction of an antigen specific Th1-to-Th2 shift could achieve this aim, once side effects, such as allergic responses, are minimized with optimal dosing.

    View details for Web of Science ID 000168240000004

    View details for PubMedID 11332658

Stanford Medicine Resources:

Footer Links: